Law office of David McEwing, P.C.

Patent and trademark attorney

 
 
 
   

DECLARATORY JUDGMENT ACTIONS AND PATENT LICENSING

 

Patent litigation is expensive.  It can easily exceed $100,000.  It is likely to be significantly more.

Recently, the US Supreme Court MedImmune v. Genentech, Inc. changed the ground rules with govern when a party may initiate a declaratory judgment action, thereby initiating patent litigation.  Prior law required that the initiating party have a “reasonable apprehension” of suit.  Now, if the initiating party can demonstration that a patentee (patent holder) asserts rights based upon the identified ongoing or planned activity of initiating party and  the initiating party contends it has the right to engage in the activity without a license to the patent holder’s patent, then the initiating party can file (initiate) a law suit (declaratory judgment) against the patent holder.

The Court of Appeals for the Federal Circuit, the final stop for most patent disputes, recently applied the Supreme Court decision and remanded (returned) a District Court decision that had refused to allow a declaratory judgment action to be commenced.

A very practical outcome of the change in ground rules is that a patent hold may not simply approach a third party and attempt licensing discussions without triggering a declaratory judgment.  A promise not to sue in not sufficient.  

Note this same case was discussed in the recent article entitled Cease and Desist.

This issue was more recently addressed by the Federal Circuit in Merck & Co. v. Apotex.  The Court applied MedImmune and affirm that the dispute must be definite and concrete, touching the legal relations of parties having adverse legal interests: ... real and substantial and admit of specific relief through a decree of a conclusive character, as distinguished from an opinion advising what the law would be upon a hypothetical state of facts.  In the Merck Apotex dispute, the Court found it could not provide any realistic relief: even with prompt action ... the final judgment sought by Apotex cannot be provided in time to be meaningful.  Accordingly, the Court concluded, the dispute presented does not admit of specific relief through a decree of a conclusive character and , thus, does not present a justiciable case or controversey.

April 28, 2007 (Updated October 10, 2008)

 

 
 

©2008 David McEwing, Registered Patent Attorney  - Web Design by The Texas Network
*The summaries contained in this site are general comments only and may not be applicable in all situations. 
They are not to be considered legal advice.  Consultation with an attorney is needed if legal advice is sought